To include your compound in the COVID-19 Resource Center, submit it here.

ABX-EGF: ABGX started an 84-patient open-label Phase II trial of weekly 2.5 mg/kg infusions of ABX-EGF in combination with standard chemotherapy (irinotecan, le

Abgenix Inc. (ABGX), Fremont, Calif.
Product: ABX-EGF
Business: Cancer
Therapeutic category:

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE